Antiva Secures $53M in Series E Funding for HPV Research
Antiva Biosciences has raised $53 million to fund two key studies of its topical drug for high-risk HPV infections and pre-cancerous lesions. The biotech will test ABI-2280 in a global Phase II clinical trial in high-grade precancerous cervical lesions and run an exploratory study to see if it can be a treatment for high-risk HPV infection.